Israel's DreaMed gets FDA ok for diabetes management software

TEL AVIV, June 18 (Reuters) - Israel's DreaMed Diabetes said on Monday the U.S. Food and Drug Administration has approved for marketing its Advisor Pro software to help manage diabetes treatment.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.